AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
Ampligen® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experiments Ampligen key to proposed...
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01